Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTBVAC PRIME
- Development stage
- Unknown
- Lead developer
- Biofabri
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
MTBVAC PRIME is a live-attenuated vaccine candidate for tuberculosis (TB) designed specifically for use in newborns. It is based on a genetically modified clinical isolate of Mycobacterium tuberculosis (Euro-American lineage), with two independent nonreverting deletion mutations in the virulence genes phoP and fadD26. This vaccine aims to stimulate immune responses that mimic natural TB infection without causing disease, and it contains the full set of antigenic targets present in virulent M. tuberculosis, including T cell epitopes absent in BCG (the current standard TB vaccine). The development was led by Dr. Carlos Martín Montañés at the University of Zaragoza and Brigitte Gicquel at Institut Pasteur[2][4][5].
- Brand names
- MTBVAC PRIME
- Other names
- MTBVAC PRIMEMTBVAC for newborns
Beyond the preview
Go deeper on MTBVAC PRIME.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTBVAC PRIME.